PRODUCT FOCUS

GIMOTI^® (metoclopramide) nasal spray is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis (DGP).

Gastroparesis is a chronic, often debilitating condition that disrupts digestion and daily life. For people with diabetes, it’s a frequent complication that leads to unpredictable symptoms like nausea, bloating, and gastric delay — making oral medications unreliable. GIMOTI is designed to address that gap.

Why GIMOTI?

• Works around the gut: GIMOTI delivers metoclopramide through the nasal route, bypassing the GI tract for more predictable absorption — even during flares or vomiting.
• Proven molecule, new delivery: GIMOTI uses the only FDA-approved drug for gastroparesis, metoclopramide, in a unique nasal spray format.
• Real-world results: Patients using GIMOTI have demonstrated fewer ER visits, hospitalizations, and office visits compared to those taking oral metoclopramide, leading to healthcare cost savings of approximately $15,000 over six months.

Supporting GLP-1 Users with Diabetic Gastroparesis

As GLP-1 receptor agonists become widely used for diabetes and obesity, reports of GI side effects, including symptoms consistent with gastroparesis, are increasing. A recent real-world study presented at ACG 2024 showed that patients taking GLP-1s and GIMOTI experienced significant reductions in office visits and fewer ER and hospital outpatient visits compared to those taking oral metoclopramide​.

These results position GIMOTI as a promising supportive therapy in patients with diabetic gastroparesis who are also on GLP-1 medications.

Please see full Prescribing Information, including Boxed Warning, and Patient Information (Medication Guide).